Vaccines Market: Overview
Vaccines help in stimulating the body’s immune system in order to produce antibodies which aid in protecting the body against infectious diseases. The administration of vaccines builds immunity in the body against the disease without contacting the disease. This report analyzes the current and future prospects of the vaccines market based on vaccine type, valance, route of administration, indication, distribution channel and geography.
Vaccines Market: Research Methodology
The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of vaccines in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for vaccine type, valance, route of administration, indication, distribution channel and geography for the period 2016 to 2025.
The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on vaccine type, valance, route of administration, indication, distribution channel and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the vaccines market in the current and future scenario. The report also provides Porter’s five force analysis that studies five factors and their impact on the vaccines market.
Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The study also covers detailed country analysis in the respective regions for the vaccines market.
The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the vaccines market include GlaxoSmithKline plc. , Sanofi Pasteur SA, Pfizer, Inc., Merck & Co., Inc., Serum Institute of India Ltd, Emergent BioSolutions Inc., CSL Ltd, Janssen Pharmaceutical Company, Novavax AB and Mitsubishi Tanabe Pharma Corporation. New product development was the primary strategy adopted by the major market players to cement their position in the vaccines market.
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Vaccines Market
4. Market Overview
4.1. Introduction
4.1.1. Vaccine Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Vaccines Market Analysis and Forecasts, 2015-2025
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Market Outlook
4.6.Key Market Trends
4.7.Global Disease Epidemiology Overview, By Key Indications
4.8.Pipeline Analysis
4.9.Unmet Needs Analysis
4.10.Pricing Analysis
4.11.Institutional Sales Overview, by Volume (No. of Unit Dose)
5. Global Vaccines Market Analysis and Forecasts, By Vaccine Type
5.1. Introduction & Definition
5.2. Key Findings/Developments
5.3. Market value Forecast By Vaccine Type, 2015-2025
5.3.1. Live Attenuated
5.3.2. Inactivated
5.3.3. Subunit & Conjugate
5.3.4. Toxoid
5.3.5. Others
5.4. Market Attractiveness By Vaccine Type
6. Global Vaccines Market Analysis and Forecasts, By Valance
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market value Forecast By Valance, 2015-2025
6.3.1. Monovalent
6.3.2. Multivalent
6.4. Market Attractiveness By Valance
7. Global Vaccines Market Analysis and Forecasts, By Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market value Forecast By Route of Administration, 2015-2025
7.3.1. Oral
7.3.2. Injectable
7.3.2.1. Intramuscular
7.3.2.2. Subcutaneous
7.3.3. Others
7.4. Market Attractiveness By Route of Administration
8. Global Vaccines Market Analysis and Forecasts, By Indication
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market value Forecast By Indication, 2015-2025
8.3.1. Influenza
8.3.2. Hepatitis
8.3.3. Polio
8.3.4. Meningococcal Disease
8.3.5. Pneumococcal Disease
8.3.6. DTP
8.3.7. Rotavirus
8.3.8. MMR
8.3.9. Human Papilloma Virus
8.3.10. Others
8.4. Market Attractiveness By Indication
9. Global Vaccines Market Analysis and Forecasts, By Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market value Forecast By Distribution Channel, 2015-2025
9.3.1. Institutional Sale
9.3.2. Hospital Pharmacies
9.3.3. Retail Pharmacies
9.4. Market Attractiveness By Distribution Channel
10. Global Vaccines Market Analysis and Forecasts, By Region
10.1.Key Findings
10.2.Market value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3.Market Attractiveness By Region
11. North America Vaccines Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.1.2. Policies and Regulations
11.2.Market value Forecast By Vaccine Type, 2015-2025
11.2.1. Live Attenuated
11.2.2. Inactivated
11.2.3. Subunit & Conjugate
11.2.4. Toxoid
11.2.5. Others
11.3.Market value Forecast By Valance, 2015-2025
11.3.1. Monovalent
11.3.2. Multivalent
11.4.Market value Forecast By Route of Administration, 2015-2025
11.4.1. Oral
11.4.2. Injectable
11.4.2.1. Intramuscular
11.4.2.2. Subcutaneous
11.4.3. Others
11.5.Market value Forecast By Indication, 2015-2025
11.5.1. Influenza
11.5.2. Hepatitis
11.5.3. Polio
11.5.4. Meningococcal Disease
11.5.5. Pneumococcal Disease
11.5.6. DTP
11.5.7. Rotavirus
11.5.8. MMR
11.5.9. Human Papilloma Virus
11.5.10. Others
11.6.Market value Forecast By Distribution Channel, 2015-2025
11.6.1. Institutional Sale
11.6.2. Hospital Pharmacies
11.6.3. Retail Pharmacies
11.7.Market value Forecast By Country, 2015-2025
11.7.1. US
11.7.2. Canada
11.8.Market Attractiveness Analysis
11.8.1. By Vaccine Type
11.8.2. By Valance
11.8.3. By Route of Administration
11.8.4. By Indication
11.8.5. By Distribution Channel
11.8.6. By Country
12. Europe Vaccines Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.1.2. Policies and Regulations
12.2.Market value Forecast By Vaccine Type, 2015-2025
12.2.1. Live Attenuated
12.2.2. Inactivated
12.2.3. Subunit & Conjugate
12.2.4. Toxoid
12.2.5. Others
12.3.Market value Forecast By Valance, 2015-2025
12.3.1. Monovalent
12.3.2. Multivalent
12.4.Market value Forecast By Route of Administration, 2015-2025
12.4.1. Oral
12.4.2. Injectable
12.4.2.1. Intramuscular
12.4.2.2. Subcutaneous
12.4.3. Others
12.5.Market value Forecast By Indication, 2015-2025
12.5.1. Influenza
12.5.2. Hepatitis
12.5.3. Polio
12.5.4. Meningococcal Disease
12.5.5. Pneumococcal Disease
12.5.6. DTP
12.5.7. Rotavirus
12.5.8. MMR
12.5.9. Human Papilloma Virus
12.5.10. Others
12.6.Market value Forecast By Distribution Channel, 2015-2025
12.6.1. Institutional Sale
12.6.2. Hospital Pharmacies
12.6.3. Retail Pharmacies
12.7.Market value Forecast By Country/Sub-region, 2015-2025
12.7.1. Germany
12.7.2. UK
12.7.3. France
12.7.4. Italy
12.7.5. Spain
12.7.6. Rest of Europe
12.8.Market Attractiveness Analysis
12.8.1. By Vaccine Type
12.8.2. By Valance
12.8.3. By Route of Administration
12.8.4. By Indication
12.8.5. By Distribution Channel
12.8.6. By Country/Sub-region
13. Asia Pacific Vaccines Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.1.2. Policies and Regulations
13.2.Market value Forecast By Vaccine Type, 2015-2025
13.2.1. Live Attenuated
13.2.2. Inactivated
13.2.3. Subunit & Conjugate
13.2.4. Toxoid
13.2.5. Others
13.3.Market value Forecast By Valance, 2015-2025
13.3.1. Monovalent
13.3.2. Multivalent
13.4.Market value Forecast By Route of Administration, 2015-2025
13.4.1. Oral
13.4.2. Injectable
13.4.2.1. Intramuscular
13.4.2.2. Subcutaneous
13.4.3. Others
13.5.Market value Forecast By Indication, 2015-2025
13.5.1. Influenza
13.5.2. Hepatitis
13.5.3. Polio
13.5.4. Meningococcal Disease
13.5.5. Pneumococcal Disease
13.5.6. DTP
13.5.7. Rotavirus
13.5.8. MMR
13.5.9. Human Papilloma Virus
13.5.10. Others
13.6.Market value Forecast By Distribution Channel, 2015-2025
13.6.1. Institutional Sale
13.6.2. Hospital Pharmacies
13.6.3. Retail Pharmacies
13.7.Market value Forecast By Country/Sub-region, 2015-2025
13.7.1. China
13.7.2. Japan
13.7.3. India
13.7.4. Rest of APAC
13.8.Market Attractiveness Analysis
13.8.1. By Vaccine Type
13.8.2. By Valance
13.8.3. By Route of Administration
13.8.4. By Indication
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Latin America Vaccines Market Analysis and Forecast
14.1.Introduction
14.1.1. Key Findings
14.1.2. Policies and Regulations
14.2.Market value Forecast By Vaccine Type, 2015-2025
14.2.1. Live Attenuated
14.2.2. Inactivated
14.2.3. Subunit & Conjugate
14.2.4. Toxoid
14.2.5. Others
14.3.Market value Forecast By Valance, 2015-2025
14.3.1. Monovalent
14.3.2. Multivalent
14.4.Market value Forecast By Route of Administration, 2015-2025
14.4.1. Oral
14.4.2. Injectable
14.4.2.1. Intramuscular
14.4.2.2. Subcutaneous
14.4.3. Others
14.5.Market value Forecast By Indication, 2015-2025
14.5.1. Influenza
14.5.2. Hepatitis
14.5.3. Polio
14.5.4. Meningococcal Disease
14.5.5. Pneumococcal Disease
14.5.6. DTP
14.5.7. Rotavirus
14.5.8. MMR
14.5.9. Human Papilloma Virus
14.5.10. Others
14.6.Market value Forecast By Distribution Channel, 2015-2025
14.6.1. Institutional Sale
14.6.2. Hospital Pharmacies
14.6.3. Retail Pharmacies
14.7.Market value Forecast By Country/Sub-region, 2015-2025
14.7.1. Brazil
14.7.2. Mexico
14.7.3. Rest of LATAM
14.8.Market Attractiveness Analysis
14.8.1. By Vaccine Type
14.8.2. By Valance
14.8.3. By Route of Administration
14.8.4. By Indication
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Middle East & Africa Vaccines Market Analysis and Forecast
15.1.Introduction
15.1.1. Key Findings
15.1.2. Policies and Regulations
15.2.Market value Forecast By Vaccine Type, 2015-2025
15.2.1. Live Attenuated
15.2.2. Inactivated
15.2.3. Subunit & Conjugate
15.2.4. Toxoid
15.2.5. Others
15.3.Market value Forecast By Valance, 2015-2025
15.3.1. Monovalent
15.3.2. Multivalent
15.4.Market value Forecast By Route of Administration, 2015-2025
15.4.1. Oral
15.4.2. Injectable
15.4.2.1. Intramuscular
15.4.2.2. Subcutaneous
15.4.3. Others
15.5.Market value Forecast By Indication, 2015-2025
15.5.1. Influenza
15.5.2. Hepatitis
15.5.3. Polio
15.5.4. Meningococcal Disease
15.5.5. Pneumococcal Disease
15.5.6. DTP
15.5.7. Rotavirus
15.5.8. MMR
15.5.9. Human Papilloma Virus
15.5.10. Others
15.6.Market value Forecast By Distribution Channel, 2015-2025
15.6.1. Institutional Sale
15.6.2. Hospital Pharmacies
15.6.3. Retail Pharmacies
15.7.Market value Forecast By Country/Sub-region, 2015-2025
15.7.1. GCC Countries
15.7.2. South Africa
15.7.3. Rest of MEA
15.8.Market Attractiveness Analysis
15.8.1. By Vaccine Type
15.8.2. By Valance
15.8.3. By Route of Administration
15.8.4. By Indication
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Competition Landscape
16.1.Market Player - Competition Matrix (By Tier and Size of companies)
16.2.Market Share Analysis By Company (2016)
16.3.Company Profiles (Details - Overview, Financials *, Recent Developments, Strategy)
16.3.1. AstraZeneca
16.3.2. GlaxoSmithKline plc
16.3.3. Sanofi Pasteur SA
16.3.4. Pfizer, Inc.
16.3.5. Panacea Biotec
16.3.6. Merck & Co., Inc.
16.3.7. Janssen Pharmaceutical Company (Part of Johnson & Johnson)
16.3.8. Serum Institute of India Ltd
16.3.9. Emergent BioSolutions Inc.
16.3.10. CSL
16.3.11. Bavarian Nordic
16.3.12. IBSS BIOMED S.A.
16.3.13. Novavax AB
16.3.14. Mitsubishi Tanabe Pharma Corporation
